More Than a List: The Ripple Effect of the Inflation Reduction Act for Patient Access & Part D

OPED: RealClear Health: The Reality of Drug Pricing Isn't a Slam Dunk for Patients by Ken Thorpe
INFOGRAPHIC: Wondering What Patients Want As the Government Implements Drug Pricing Policies?
SIGN ON LETTER: Preserving Access to Small Molecule Medicines
Commentary from the Patient Community on the Implentation of the Inflation Reduction Act
CMS has published its list of the first 10 Medicare Part D medicines selected for price setting under the Inflation Reduction Act (IRA). The announcement initiates a series of changes that will have a tremendous ripple effect throughout the Part D program and further – from initial investments to research and development and ultimately, the delivery of treatments and cures to millions of patients with increasing unmet medical needs. Added to that are expected formulary restrictions and expanded utilization management, for example, that will impact seniors’ access to medicines and exacerbate the demands on our already ailing healthcare system.
On August 1, the Partnership to Fight Chronic Disease (PFCD) convened leading stakeholder voices together to explore the broader impact the CMS announcement will have on the Part D program, patient access, pipelines for treatments and cures, and more.
PANEL ONE: What does drug selection mean for patients?

  • Dr. Seth Baum, MD, Partnership to Advance Cardiovascular Health
  • Erin Callahan, Diabetes Patient Advocacy Coalition & Diabetes Leadership Council
  • Tom McCoy, Nevada Chronic Care Collaborative
  • Heidi Ross, NORD
  • Moderator: Sue Peschin, Alliance for Aging Research

PANEL TWO: What does drug selection mean for the broader healthcare ecosystem?

  • Kirsten Axelsen, DLA Piper
  • Peter Rubin, No Patient Left Behind
  • Ipsita Smolenski, Capitol Street
  • Ken Thorpe, Partnership to Fight Chronic Disease
  • Moderator: Debbie Witchey, Healthcare Leadership Council